Royal Bank of Canada Sells 23,345 Shares of Charles River Laboratories International, Inc. $CRL

Royal Bank of Canada reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 18.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,311 shares of the medical research company’s stock after selling 23,345 shares during the period. Royal Bank of Canada owned 0.21% of Charles River Laboratories International worth $17,303,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ranger Investment Management L.P. bought a new position in shares of Charles River Laboratories International during the first quarter valued at approximately $12,198,000. The Manufacturers Life Insurance Company boosted its position in shares of Charles River Laboratories International by 17.4% in the 1st quarter. The Manufacturers Life Insurance Company now owns 43,471 shares of the medical research company’s stock worth $7,499,000 after purchasing an additional 6,444 shares in the last quarter. Maverick Capital Ltd. bought a new stake in shares of Charles River Laboratories International in the 1st quarter worth approximately $1,411,000. Lazard Asset Management LLC grew its stake in shares of Charles River Laboratories International by 13.2% in the 1st quarter. Lazard Asset Management LLC now owns 22,637 shares of the medical research company’s stock worth $3,905,000 after buying an additional 2,644 shares during the last quarter. Finally, Castleark Management LLC increased its position in Charles River Laboratories International by 22.3% during the 1st quarter. Castleark Management LLC now owns 39,435 shares of the medical research company’s stock valued at $6,803,000 after buying an additional 7,190 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Q2 results exceeded expectations: Charles River reported adjusted earnings of $3.02 per share, above the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $977.2 million. The earnings beat came despite revenue declining 2.7% year over year. Charles River Q2 earnings report
• Positive Sentiment: Full-year guidance was raised: Management now expects fiscal 2026 adjusted EPS of $11.15-$11.45, above the $11.09 consensus estimate, and revenue of roughly $3.9 billion versus Wall Street expectations of $3.8 billion. The company also raised its free-cash-flow forecast to $400 million-$420 million. Charles River 2026 outlook
• Positive Sentiment: Demand trends are improving: Charles River cited stronger biotech demand for its discovery and development services. Analysts highlighted improving organic revenue and order trends, strong backlog and book-to-bill performance in the Discovery and Safety Assessment segment, and anticipated margin benefits from divestitures and cost reductions. Charles River lifts profit forecast
• Positive Sentiment: JPMorgan upgraded CRL: JPMorgan moved its rating from “neutral” to “overweight” and raised its price target to $310 from $180, signaling greater confidence in the company’s recovery and earnings trajectory.
• Neutral Sentiment: Executive stock sale: EVP Shannon M. Parisotto sold 5,046 shares for approximately $1.33 million under a pre-arranged Rule 10b5-1 trading plan. Although the sale reduced her direct holdings by more than half, the planned nature of the transaction makes it a limited near-term signal about management’s outlook. SEC insider transaction filing
• Negative Sentiment: Underlying risks remain: Quarterly EPS fell from $3.12 a year earlier, revenue declined year over year, and the Resources Management Services segment continues to face weakness in the U.S. These issues could limit the durability of the rally if demand improvement slows.

Insider Transactions at Charles River Laboratories International

In related news, EVP Shannon M. Parisotto sold 5,046 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $263.00, for a total transaction of $1,327,098.00. Following the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,264,241. This represents a 51.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the sale, the director owned 31,596 shares in the company, valued at $7,109,100. This represents a 70.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Up 1.9%

CRL stock opened at $265.73 on Friday. The stock has a market capitalization of $12.80 billion, a P/E ratio of -54.79, a P/E/G ratio of 2.86 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.03. Charles River Laboratories International, Inc. has a 1-year low of $144.26 and a 1-year high of $268.00. The business has a fifty day moving average price of $213.14 and a 200-day moving average price of $188.71.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, beating the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. During the same period last year, the firm posted $3.12 earnings per share. Charles River Laboratories International’s revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts forecast that Charles River Laboratories International, Inc. will post 11.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Weiss Ratings upgraded Charles River Laboratories International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. CLSA lowered Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target for the company. in a research report on Monday, July 20th. BNP Paribas Exane set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Evercore reissued an “outperform” rating on shares of Charles River Laboratories International in a research report on Wednesday. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and an average price target of $244.19.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.